🇺🇸 FDA
Pipeline program

CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI

CA017-078

Phase 3 small_molecule active

Quick answer

CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, OPDIVO 10 mg/mL concentrate for solution for infusion., Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI for Bladder Cancer Muscle-Invasive Bladder Cancer is a Phase 3 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).

Program details

Company
Bristol-Myers Squibb / Pfizer EEIG
Indication
Bladder Cancer Muscle-Invasive Bladder Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials